Biopharma Leaders Pledge Politics Won't Impact COVID-19 Vaccine Development
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), early Tuesday pledged their commitment to science as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.
A Vancouver-based biotech company brought its genetic know-how to Pfizer's COVID-19 vaccine development. Thomas Madden, president and CEO of Acuitas Therapeutics, explains his company's contribution to the vaccine effort.
»» First lady Melania Trump campaigned for her husband in North Carolina the day before the election. She slammed critics of a potential Covid-19 vaccine, saying it should not be dismissed simply because it may happen under President Trump's leadership. Gov. Gavin Newsom said California will review the safety of all COVID-19 vaccines approved by the Trump administration before allowing them to be released to the public. COVID-19 vaccine trials don't currently include children under 12, says Health Canada's chief medical adviser, Supriya Sharma. She says that means vaccination efforts will first focus on adults.